QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IOVA

QT74Iovance Biotherapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
3.91
-0.02-0.51%
OverviewShort InterestFilings
IOVAQT74Iovance Biotherapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
3.91-0.51%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.92
Insider Own7.18%
Shs Outstand446.50M
Perf Week-1.26%
Market Cap1.41BForward P/E-EPS next Y-0.31Insider Trans0.24%Shs Float-Perf Month13.01%
Enterprise Value1.26BPEG-EPS next Q-0.17Inst Own-Short Float-Perf Quarter1.03%
Income-302238223.00P/S4.92EPS this Y40.29%Inst Trans-Short Ratio-Perf Half Y73.78%
Sales285.61MP/B2.28EPS next Y43.74%ROA-38.23%Short Interest-Perf YTD43.22%
Book/sh1.62P/C-EPS next 5Y-ROE-50.17%52W High5.63 -30.55%Perf Year93.56%
Cash/sh0.70P/FCF-EPS past 3/5Y-ROIC-45.27%52W Low1.66 135.54%Perf 3Y-
Dividend Est.-EV/EBITDA-3.91Sales past 3/5Y-Gross Margin114.51%Volatility4.62% 5.33%Perf 5Y-
Dividend TTM-EV/Sales4.40EPS Y/Y TTM25.78%Oper. Margin-127.16%ATR (14)0.32Perf 10Y-
Dividend Ex-Date-Quick Ratio3.15Sales Y/Y TTM73.78%Profit Margin-123.90%RSI (14)50.12Recom2.00
Dividend Gr. 3/5Y-Current Ratio3.60EPS Q/Q47.22%SMA20-2.89%Beta1.78Target Price4.00
Payout0.00%Debt/Eq0.07Sales Q/Q44.90%SMA503.44%Rel Volume1.56Prev Close3.93
Employees838LT Debt/Eq0.06EarningsAug 06SMA20031.71%Avg Volume15.14MPrice3.91
IPO DateOct 15, 2010Option/ShortYes / YesEPS/Sales Surpr.0.00% -8.97%Net Debt/EBITDA0.46Volume23,650,164Change-0.51%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26ReiteratedNational Bank$5.00
Jun-01-26ReiteratedWells FargoOverweight$25 → $5.00
Mar-03-26UpgradeCitizensMarket Perform → Market Outperform
Feb-25-26UpgradeCitizensMarket Perform → Market Outperform
Feb-05-26ReiteratedGoldman SachsBuy$1.50 → $2.00
May-16-25DowngradeUBSBuy → Neutral$17 → $2.00
May-09-25DowngradeJMP SecuritiesMarket Outperform → Market Perform
Feb-28-25ReiteratedPiper SandlerNeutral$7.50 → $6.00
Jan-31-25ReiteratedPiper SandlerNeutral$10 → $7.50
Oct-24-24ReiteratedUBS$17
Latest News
Jun-17-26
Jun-17-2611:31AM
Iovance Biotherapeutics: Commercial, Clinical And Regulatory TailwindsSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue285264164
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A-427124
Gross Profit32625640
Selling, General and Administrative Excl. Other148152153
Research and Development285300282
Other Operating Expense2572080
Operating Income-363-403-395
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-8-10-20
Net Income Before Taxes-356-393-375
Income Taxes-1-2-3
Consolidated Net Income-354-391-372
Net Income From Continuing Operations-354-391-372
Net Income-354-391-372
EPS (Recurring)-0.92-1.09-1.28
EPS (Basic, Before Extraordinaries)-0.92-1.09-1.28
EPS (Diluted)-0.92-1.09-1.28
EBITDA-322-357-331
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio5.753.69—
Gross Margin114.3996.9724.39
Operating Margin-127.37-152.65-240.85
Net Margin-124.21-148.11-226.83
Shares Outstanding419357290
Market Capitalization1,638975—
Operating Lease Expense
———
Insider Trading Volume
$4.11$3.77$3.43$3.09$2.75● Close Price0.00K13.80K27.60K41.40K55.20KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 05 '26Option Exercise0.0015,6260144,087Jun 09 12:00 AM
Puri Raj K.Chief Regulatory OfficerJun 05 '26Option Exercise0.0019,5320251,957Jun 09 12:00 AM
Vogt Frederick GInterim CEO & General CounselJun 05 '26Option Exercise0.0031,2500569,130Jun 09 12:00 AM
BILINSKY IGORChief Operating OfficerJun 05 '26Option Exercise0.0015,6260137,896Jun 09 12:00 AM
Vogt Frederick GInterim CEO & General CounselJun 01 '26Option Exercise0.0083,3360571,206Jun 03 12:00 AM
Puri Raj K.Chief Regulatory OfficerJun 01 '26Option Exercise0.0010,9380244,699Jun 03 12:00 AM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 01 '26Option Exercise0.0017,5800140,747Jun 03 12:00 AM
BILINSKY IGORChief Operating OfficerJun 01 '26Option Exercise0.0017,5800134,556Jun 03 12:00 AM
Kirby Daniel GordonChief Commercial OfficerMay 11 '26Option Exercise0.0020,0000149,381May 13 12:00 AM
Vogt Frederick GInterim CEO & General CounselMar 05 '26Option Exercise0.00124,9860556,293Mar 06 12:00 AM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerMar 05 '26Option Exercise0.0062,4920148,477Mar 06 12:00 AM
Puri Raj K.Chief Regulatory OfficerMar 05 '26Option Exercise0.0078,1180257,590Mar 06 12:00 AM
BILINSKY IGORChief Operating OfficerMar 05 '26Option Exercise0.0062,4920142,394Mar 06 12:00 AM
Puri Raj K.Chief Regulatory OfficerMar 02 '26Option Exercise0.0010,9400221,329Mar 04 12:00 AM
Vogt Frederick GInterim CEO & General CounselMar 02 '26Option Exercise0.00104,1740516,609Mar 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR